Company intelligence / Profile preview

iTheranostics

Dover, Delaware, United States

Ownership: Private
Development stage: Other

Overview

iTheranostics developed a library of fibroblast activation protein (FAP) targeting agents, including FAPI-46 and FAPI-74, for radiopharmaceutical imaging and therapy. The company licensed global therapeutic rights of these compounds to Novartis for clinical development, while retaining responsibilities for commercializing imaging tracers. The clinical stage of the compounds themselves in Novartis's hands is not public, but as of the deal, they were pre-clinical to early clinical.

Therapeutic areas: Oncology
Modalities: RadiopharmaceuticalRadioligandSmall molecule
Industry: Biotech

Partnerships

NovartisUniversity of Heidelberg (original IP licensor)

Beyond the preview

Go deeper on iTheranostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iTheranostics.

Explore the full profile